These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 16298571)

  • 1. Impact of mycophenolate mofetil intolerance on early results of kidney transplantation.
    Kahu J; Kyllönen L; Salmela K
    Transplant Proc; 2005 Oct; 37(8):3276-9. PubMed ID: 16298571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.
    Bunnapradist S; Lentine KL; Burroughs TE; Pinsky BW; Hardinger KL; Brennan DC; Schnitzler MA
    Transplantation; 2006 Jul; 82(1):102-7. PubMed ID: 16861948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation.
    Cherikh WS; Myron Kauffman H; Maghirang J; Bleyer AJ; Johnson CP
    Transplantation; 2003 Aug; 76(3):463-70. PubMed ID: 12923430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.
    Boratyńska M; Banasik M; Patrzałek D; Klinger M
    Ann Transplant; 2006; 11(2):51-6. PubMed ID: 17494290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the calcineurin inhibitor of choice for pediatric renal transplantation?
    Kari JA; Trompeter RS
    Pediatr Transplant; 2004 Oct; 8(5):437-44. PubMed ID: 15367278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil tolerability and dose changes in tacrolimus-treated renal allograft recipients.
    Pascual J; Ocaña J; Marcén R; Fernández A; Galeano C; Alarcón MC; Burgos FJ; Villafruela JJ; Ortuño J
    Transplant Proc; 2006 Oct; 38(8):2398-9. PubMed ID: 17097946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
    Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients.
    Tierce JC; Porterfield-Baxa J; Petrilla AA; Kilburg A; Ferguson RM
    Clin Transplant; 2005 Dec; 19(6):779-84. PubMed ID: 16313325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients.
    Sun Q; Liu ZH; Yin G; Chen H; Chen J; Ji S; Li LS
    Nephrol Dial Transplant; 2006 Feb; 21(2):510-7. PubMed ID: 16421166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective use of mycophenolate mofetil in renal transplant patients in Indian scenario.
    Srivastava A; Singh V; Kumar A; Sharma RK; Gupta A
    Transplant Proc; 2004 Sep; 36(7):2060-4. PubMed ID: 15518746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric renal transplantation with mycophenolate mofetil immunosuppression in a single center from Mexico.
    Martinez-Mier G; Mendez-Lopez MT; Budar-Fernandez LF; Estrada-Oros J; Franco-Abaroa R; George-Micelli E; Rios-Martinez L; Calzada-Grijalva JF; Gonzalez-Velazquez F
    Pediatr Transplant; 2007 Mar; 11(2):134-8. PubMed ID: 17300491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens.
    Wlodarczyk Z; Walaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradszky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Kalmar KN; Hickey D
    Transpl Int; 2005 Feb; 18(2):157-62. PubMed ID: 15691267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
    Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
    Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.